1092540-56-1

Basic information

• Product Name: Deuterated Atazanivir
• Synonyms: Deuterated Atazanivir;(3S,8S,9S,12S)-3-(1,1-Dimethylethyl)-12-[1,1-di(methyl-d3)ethyl-2,2,2-d3]-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid 1,14-di(methyl-d3) ester;DeuteratedAtazanivir-D3-1
• CAS NO: 1092540-56-1
• Molecular Formula: C₃₈H₅₂N₆O₇
• Molecular Weight: 719.94790667
• EINECS: -0
• Mol File: 1092540-56-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Deuterated Atazanivir(CAS DataBase Reference)
• NIST Chemistry Reference: Deuterated Atazanivir(1092540-56-1)
• EPA Substance Registry System: Deuterated Atazanivir(1092540-56-1)

Safety Data

• Hazardous Substances Data: 1092540-56-1(Hazardous Substances Data)

Usage

Description

Deuterated Atazanivir is a modified form of the antiretroviral drug atazanavir, which is used in the treatment of HIV infection. It is created by substituting deuterium, a stable isotope of hydrogen, for some of the hydrogen atoms in atazanavir. This modification alters the pharmacokinetics of the drug, resulting in a longer half-life and slower metabolism in the body. It is believed that deuterated atazanavir may offer improved efficacy, reduced dosing frequency, and decreased side effects compared to atazanavir.

Uses

Used in HIV Treatment:
Deuterated Atazanivir is used as an antiretroviral agent for the treatment of HIV infection. The deuterium substitution in the drug molecule is believed to enhance its efficacy, reduce dosing frequency, and decrease side effects compared to the original atazanavir.
Clinical trials are ongoing to evaluate the safety and efficacy of deuterated atazanavir in the treatment of HIV. The modified pharmacokinetics, including a longer half-life and slower metabolism, may contribute to better patient adherence and treatment outcomes.

Upstream product

• 1092539-96-2 (S)-2-(d3-methoxy-carbonylamino)-3,3-d9-dimethylbutanoic acid 

Relevant articles and documents

Azapeptide derivatives as HIV protease inhibitors

This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.